(Q37730394)

22 August 2017

1 reference

title

Optimal use of targeted agents for advanced gastrointestinal stromal tumours (English)

1 reference

22 August 2017

Peter Reichardt

1

1 reference

22 August 2017

publication date

13 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

78

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

130-140

1 reference

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

22 August 2017

cites work

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

12 December 2020

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

1 reference

12 December 2020

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

12 December 2020

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

1 reference

12 December 2020

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

12 December 2020

Developments in targeted therapy of advanced gastrointestinal stromal tumors.

1 reference

12 December 2020

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

1 reference

12 December 2020

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

12 December 2020

Clinical implications of mutational analysis in gastrointestinal stromal tumours

1 reference

12 December 2020

Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

1 reference

12 December 2020

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor

1 reference

12 December 2020

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

12 December 2020

Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.

1 reference

12 December 2020

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

12 December 2020

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

12 December 2020

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients

1 reference

12 December 2020

Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?

1 reference

12 December 2020

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.

1 reference

12 December 2020

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

1 reference

12 December 2020

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

12 December 2020

Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study.

1 reference

12 December 2020

We should desist using RECIST, at least in GIST.

1 reference

12 December 2020

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

1 reference

12 December 2020

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment

1 reference

12 December 2020

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

12 December 2020

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

12 December 2020

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

1 reference

12 December 2020

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

1 reference

12 December 2020

Novel approaches to imatinib- and sunitinib-resistant GIST.

1 reference

12 December 2020

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

12 December 2020

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

1 reference

12 December 2020

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

1 reference

12 December 2020

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 reference

12 December 2020

New therapeutic approaches for advanced gastrointestinal stromal tumors

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

12 December 2020

Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up.

1 reference

12 December 2020

Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group

1 reference

12 December 2020

Identifiers

DOI

10.1159/000312655

1 reference

22 August 2017

1 reference